Cover Image
市場調查報告書

癌症治療藥的產業及市場:治療藥、R&D與預測

Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024

出版商 Visiongain Ltd 商品編碼 273854
出版日期 內容資訊 英文 275 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症治療藥的產業及市場:治療藥、R&D與預測 Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024
出版日期: 2014年08月06日 內容資訊: 英文 275 Pages
簡介

本報告提供抗癌藥以及其他的癌症治療藥的市場相關調查、各療法的市場收益預測、主要國家的市場收益預測、主要25個產品的市場收益預測、新的認證核可藥與可能性的檢驗、主要企業的配合措施、癌症的各類型的研發產品線狀況、專家的採訪等詳細彙整。

第1章 報告概要

第2章 癌症治療:簡介

  • 癌症的生理學:原因及影響
  • 癌症的罹患率和得病率:全球趨勢
  • 腫瘤的治療

第3章 全球癌症治療藥市場預測

  • 全球癌症治療藥治療市場預測
  • 主流的免疫療法
  • 免疫療法用藥物的市場預測:最快成長部門
  • 化療藥物的市場預測
  • 標靶治療藥的市場預測:個體化的動機
  • 荷爾蒙治療藥物的市場預測

第4章 主要國家市場預測

  • 癌症治療藥:主要國家市場
  • 美國的癌症治療藥市場預測
  • 日本的癌症治療藥市場預測
  • 歐洲5個國家的癌症治療藥市場預測
  • 金磚四國的癌症治療藥市場預測

第5章 癌症治療藥25大產品的收益預測

  • Avastin (Roche)
  • Herceptin (Roche)
  • Rituxan/MabThera (Roche)
  • Gleevec/Glivec (Novartis)
  • Revlimid (Celgene)
  • Alimta (Eli Lilly)
  • Velcade (J&J/Takeda)
  • Erbitux (Bristol-Myers Squibb/ Merck KGaA)
  • Gardasil (Merck & Co)
  • Zytiga (Johnson & Johnson)
  • Xeloda (Roche)
  • Tarceva (Roche)
  • Afinitor (Novartis)
  • Sprycel (Bristol-Myers Squibb)
  • Tasigna (Novartis)
  • Sutent (Pfizer)
  • Nexavar (Bayer/Onyx Pharmaceuticals)
  • Xgeva (Amgen)
  • Zoladex (AstraZeneca)
  • Yervoy (Bristol-Myers Squibb)
  • Vidaza (Celgene)
  • Treanda (Teva Pharmaceuticals)
  • Temodar/Temodal (Merck & Co.)
  • Faslodex (AstraZeneca)
  • Abraxane (Celgene)

第6章 2013年、2014年的認證核可藥

第7章 癌症治療藥的主要企業

  • 7大公司佔據大部分的癌症治療藥市場
  • Roche
  • Novartis
  • Celgene
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck & Co.

第8章 癌症治療藥的研發產品線

  • 乳癌
  • 前列腺癌
  • 肺癌
  • 大腸癌
  • 子宮頸癌
  • 胃癌
  • 肝癌
  • 卵巢癌
  • 膀胱癌
  • 非何杰金氏淋巴瘤
  • 白血病
  • 腎臟癌
  • 胰臟癌

第9章 癌症治療藥市場定性分析

  • SWOT分析
  • STEP分析

第10章 專家的採訪

  • Thomas Felzmann(CEO, Activartis Biotech GmbH)
  • Philip Rudland教授(University of Liverpool)
  • Sidong Huang博士(McGill University)
  • Neil Butt博士(Antitope Ltd.)

第11章 結論

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Cancer treatments - here's your guide to R&D and sales potentials

Do you want to assess the future of cancer-treating medicines? Visiongain's new report gives you revenue predictions for that industry from 2014, helping you stay ahead. You find financial data, R&D trends, opportunities and outlooks for therapy.

In that analysis you see forecasted sales to 2024 at overall world market, submarket, product and national level. You also assess emerging trends, technologies, and expected therapies.

Events shaping that pharmaceuticals industry - why cancer remains healthcare's top priority

Discover, then, what the future holds for anti-cancer products. And find how patients can benefit. Read on to explore that industry and see what its future market could be worth.

Forecasts to 2024 and other analyses show you sales prospects

Besides revenue forecasting to 2024, you find historical data, growth rates and market shares. You assess quantitative and qualitative analyses, business news, outlooks and developments (R&D). You also gain 128 tables, 145 charts and four interviews.

Is finding data for cancer treatment a challenge? Finding information there just got easier. Our work lets you investigate the most promising and lucrative parts of applied oncology. Avoid missing out. Instead you can stay ahead in knowledge and benefit your influence.

Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses and decisions for medicines including biological drugs (biologics).

And the following sections show how you gain from our new investigation.

Outlooks for that world market and its submarkets - where does the money lie?

Along with prediction of overall world market value to 2024, our report shows you individual revenue forecasting of four submarkets at world level:

  • Immunotherapy
  • Chemotherapies
  • Targeted treatments
  • Hormone-based agents.

Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. Assess leading brands too.

Forecasts for 25 leading drugs and 23 emerging therapies - see potentials

How will leading drugs perform to 2024 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:

  • Avastin
  • Herceptin
  • Rituxan/MabThera
  • Glivec/Gleevec
  • Revlimid
  • Alimta
  • Velcade.

You also discover individual selling potentials of 23 rising and emerging therapies, including these:

  • Beleodaq
  • Zykadia
  • Cyramza
  • Imbruvica
  • Gazyva.

There you discover how high sales can go, to 2024, finding drugs and years with highest predicted growth and revenues. You see what's happening, then, understanding trends, competition, challenges and opportunities.

In our study you also find geographical revenue predictions.

Leading national markets - where lie highest revenues and growth?

Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2014. See where and how.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
  • Brazil, Russia, India and China (BRIC nations).

There you find potential. Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2014 to 2024 will change medical prescribing and the commercial landscape. See what's possible for R&D.

Research and development - assess innovation, trends and possibilities

What's happening in oncological R&D? You find trends for treating these cancers:

  • Bladder
  • Brain
  • Breast
  • Cervix
  • Gut
  • Kidney
  • Leukaemia
  • Liver
  • Lung.

Our study also discusses products in development for these cancers:

  • Lymphoma
  • Multiple myeloma
  • Ovary
  • Pancreas
  • Prostate
  • Sarcoma and skin
  • Stomach
  • Other related diseases and neoplasms, including solid tumours (tumors).

R&D in oncology holds strength, variety and promise. You assess innovations for those disorders, hearing about developments and finding their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also see what shapes that market from 2014.

Forces affecting the industry and market for anti-cancer medicines

Our report discusses issues and events affecting that industry and market from 2014, including these:

  • Epidemiology - incidence, prevalence, mortality and survival
  • Resistance to treatment, tumour (tumour) heterogeneity, dedifferentiation, invasiveness and metastasis
  • Personalised medicine, targeted therapy, in vivo diagnostics (IVD) and theranostics
  • Cost-effectiveness, pricing and reimbursement
  • Payers and healthcare policy.

The study also discusses other aspects of cancer treatment, including these:

  • Monoclonal antibodies (mAbs), cancer vaccines and others, inc. blockbusters
  • Efficacy, cytotoxicity and improving treatment effectiveness and safety
  • Biosimilars (follow-on-protein products) and generics (generic drugs)
  • Genomics and genome screening
  • Biomarkers and diagnostic tests.

That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that business. You also analyse the anti-cancer drug industry's strengths, weaknesses, opportunities and threats (SWOT).

Discover what the future holds.

Leading companies in cancer treatment and 2018 market value

From 2014, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $122.3bn in 2018, expanding further to 2024. What's possible there?

Our analysis shows you what technologies, products and organisations hold greatest potential. They cover these leading companies, among others:

  • Roche
  • Novartis
  • Celgene
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck & Co.

Prospects for sales and R&D in oncology are strong, and from 2014 there will arise many opportunities. See where. Our report shows you the possibilities, helping you stay ahead.

Eight ways Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024 helps you

In particular, our new analysis gives the following knowledge to help your work:

  • World anti-cancer drugs market revenue to 2024 - discover the sales potential of that industry
  • Four product classes' revenues to 2024 - investigate categories at world level, finding the most lucrative and promising groups
  • 25 leading drugs and 23 emerging and rising therapies' revenues to 2024 - find sales predictions for top treatments, seeing how they can compete and succeed
  • 11 national markets in the Americas, Europe and Asia - forecasts to 2024 - discover the best countries and regions for commercial expansion
  • Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances and outlooks
  • Research and development (R&D) - investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities
  • Interviews with four organisations - discover other experts' views, gaining feel for that industry
  • Analysis of what stimulates and restrains the cancer treatments industry and market - assess challenges and strengths, helping you find advantages and succeed.

Data there found nowhere else, benefiting your influence in pharma biotechnology

  • Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where business prospects are most rewarding.

With that investigation you're less likely to fall behind in data or miss opportunity. Discover there, by your choice, how to help your information searches, analyses and decisions. Also find how you could save time and gain in authority for technological and commercial insight.

Trying our report now lets you discover biopharma opportunities and predictions

  • Our new report is for everyone analysing cancer-treating drugs. There you find trends, opportunities and sales predictions. Avoid missing out - please get that study here now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Cancer-Treating Drugs
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by this Analysis
  • 1.5 Who is this Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Cancer Treatments

  • 2.1 The Physiology of Cancer - Causes and Effects
    • 2.1.1 Uncontrolled Growth
    • 2.1.2 Dedifferentiation
    • 2.1.3 Invasiveness and Metastasis
    • 2.1.4 Causes of Cancer
  • 2.2 The Incidence and Prevalence of Cancer - Trends in the World
    • 2.2.1 Incidence
    • 2.2.2 Mortality
    • 2.2.3 Survival - Improving Odds
      • 2.2.3.1 The Developed World
      • 2.2.3.2 The Developing World - More Must Be Done
  • 2.3 Treating Tumours - How Can We Fight Back?
    • 2.3.1 Chemotherapy - The Traditional Treatment
    • 2.3.2 Hormone Therapies
    • 2.3.3 Immunotherapy - A Magic Bullet?
      • 2.3.3.1 Monoclonal Antibodies (mAbs)
      • 2.3.3.2 Cancer Vaccines
      • 2.3.3.3 Non-Specific Immunotherapies
    • 2.3.4 Targeted Therapies
    • 2.3.5 Differentiating Agents

3. The World Anti-Cancer Drug Market, 2014-2024

  • 3.1 Global Anti-Cancer Drugs Market Forecast, 2014-2024
  • 3.2 The Domination of Immunotherapies in 2013
  • 3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2014-2024 - The Fastest Growing Segment
  • 3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2014-2024
  • 3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2014-2024 - A Move towards Personalisation
  • 3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2014-2024

4. Leading National Markets, 2014-2024

  • 4.1 Anti-Cancer Drugs - Leading Markets, 2013
  • 4.2 The US Anti-Cancer Drugs Market, 2014-2024 - Continued Leadership or Terminal Decline?
    • 4.2.1 The US Anti-Cancer Drugs Market, 2013
    • 4.2.2 The US Anti-Cancer Drugs Market Forecast - A Matured Approach
    • 4.2.3 The Regulatory Effect on the US Market
  • 4.3 The Japanese Anti-Cancer Drug Market, 2014-2024 - Still Steady?
  • 4.4 The EU5 Anti-Cancer Drugs Market, 2014-2024 - Rivalling the US in Importance
  • 4.5 The BRIC Countries Anti-Cancer Drugs Market, 2014-2024 - Awakening Sleeping Giants?
    • 4.5.1 The Brazilian Anti-Cancer Drugs Market, 2014-2024 - Expansion of the Middle Class
    • 4.5.2 The Russian Anti-Cancer Drugs Market, 2014-2024 - Rising Cancer Rates Stimulate Revenue Increases
    • 4.5.3 The Indian Anti-Cancer Drugs Market, 2014-2024 - Lucrative Opportunity for Growth
    • 4.5.4 The Chinese Anti-Cancer Drugs Market, 2014-2024 - Can it Fulfil its Potential?

5. The Top 25 Anti-Cancer Drugs, 2014-2024

  • 5.1 Avastin (Roche) - The World Market Leader
    • 5.1.1 Avastin Revenue, 2010-2013 - Mixed Growth
    • 5.1.2 Avastin Revenue Forecast - Still No.1?
  • 5.2 Herceptin (Roche) - The Looming Impact of Patent Expiry
    • 5.2.1 Herceptin Revenue, 2010-2013 - Still Rising
    • 5.2.2 Herceptin Revenue Forecast - Generic Erosion
  • 5.3 Rituxan/MabThera (Roche) - Slowing Growth
    • 5.3.1 Rituxan Revenue, 2010-2013 - Still Strong
    • 5.3.2 Rituxan Revenue Forecast - Heading for a Decline
  • 5.4 Gleevec/Glivec (Novartis) - The Maturation of a Blockbuster
    • 5.4.1 Glivec Revenue, 2010-2013
    • 5.4.2 Glivec Revenue Forecast - What Does the Future Hold?
  • 5.5 Revlimid (Celgene) - Celgene's Top Revenue Generator
    • 5.5.1 Revlimid Revenue, 2010-2013 - Still on the Rise
    • 5.5.2 Revlimid Revenue Forecast - A Long Term Leader?
  • 5.6 Alimta (Eli Lilly) - A Slow Decline?
    • 5.6.1 Alimta Revenue, 2010-2013
    • 5.6.2 Alimta Revenue Forecast- Revenue Erosion Looming
  • 5.7 Velcade (J&J/Takeda) - Rising Steadily
    • 5.7.1 Velcade Revenue, 2010-2013
    • 5.7.2 Velcade Revenue Forecast - A Dependable Sales Generator
  • 5.8 Erbitux (Bristol-Myers Squibb/ Merck KGaA) - Facing Tough Competition
    • 5.8.1 Erbitux Revenue, 2010-2013
    • 5.8.2 Erbitux Revenue Forecast - No More Growth?
  • 5.9 Gardasil (Merck & Co) - The Rise of Preventions
    • 5.9.1 Gardasil Revenue, 2010-2013
    • 5.9.2 Gardasil Revenue Forecast - Still Growing Strong
  • 5.10 Zytiga (Johnson & Johnson)
    • 5.10.1 Zytiga Revenue, 2010-2013 - The Rise of a New Drug
    • 5.10.2 Zytiga Revenue Forecast
  • 5.11 Xeloda (Roche) - Patent Exclusivity and the Future
    • 5.11.1 Xeloda Revenue, 2010-2013 - The Impact of Combination Therapies
    • 5.11.2 Xeloda Revenue Forecast - A Slippery Slope
  • 5.12 Tarceva (Roche)
    • 5.12.1 Tarceva Revenue, 2010-2013 - No Clear Pattern
    • 5.12.2 Tarceva Revenue Forecast
  • 5.13 Afinitor (Novartis) - A Targeted Approach
    • 5.13.1 Afinitor Revenue, 2010-2013 - Growing Fast
    • 5.13.2 Afinitor Revenue Forecast
  • 5.14 Sprycel (Bristol-Myers Squibb)
    • 5.14.1 Sprycel Revenue, 2010-2013
    • 5.14.2 Sprycel Revenue Forecast - How Long Will the Growth Last?
  • 5.15 Tasigna (Novartis) - Moving on Up
    • 5.15.1 Tasigna Revenue, 2010-2013
    • 5.15.2 Tasigna Revenue Forecast - A Multi-Billion Dollar Product?
  • 5.16 Sutent (Pfizer)
    • 5.16.1 Sutent Revenue, 2010-2013
    • 5.16.2 Sutent Revenue Forecast - No More Growth
  • 5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
    • 5.17.1 Nexavar Revenue, 2010-2013 - The Effect of Regional Sales
    • 5.17.2 Nexavar Revenue Forecast - A Promising Start to the Decade
  • 5.18 Xgeva (Amgen)
    • 5.18.1 Xgeva Revenue, 2010-2013 - The Impact of New Indications
    • 5.18.2 Xgeva Revenue Forecast
  • 5.19 Zoladex (AstraZeneca)
    • 5.19.1 Zoladex Revenue, 2010-2013
    • 5.19.2 Zoladex Revenue Forecast
  • 5.20 Yervoy (Bristol-Myers Squibb) - Starting to Make its Mark
    • 5.20.1 Yervoy Revenue, 2011-2013
    • 5.20.2 Yervoy Revenue Forecast - Will it Keep Growing?
  • 5.21 Vidaza (Celgene) - What Growth Potential?
    • 5.21.1 Vidaza Revenue, 2010-2013
    • 5.21.2 Vidaza Revenue Forecast - Generic Impact
  • 5.22 Treanda (Teva Pharmaceuticals)
    • 5.22.1 Treanda Revenue, 2010-2013
    • 5.22.2 Treanda Revenue Forecast - Stalled Growth?
  • 5.23 Temodar/Temodal (Merck & Co.) - Falling off the Cliff?
    • 5.23.1 Temodar/Temodal Revenue, 2010-2013
    • 5.23.2 Temodar/Temodal Revenue Forecast
  • 5.24 Faslodex (AstraZeneca) - The Counterpart to Zoladex
    • 5.24.1 Faslodex Revenue, 2010-2013
    • 5.24.2 Faslodex Revenue Forecast
  • 5.25 Abraxane (Celgene) - Beginning the Climb
    • 5.25.1 Abraxane Revenue, 2012-2013
    • 5.25.2 Abraxane Revenue Forecast

6. Drugs Approved in 2013-2014: Potential Future Blockbusters

  • 6.1 Approved Treatments in 2014
    • 6.1.1 Beleodaq (Topotarget/Spectrum Pharmaceuticals)
      • 6.1.1.1 Market Potential
    • 6.1.2 Zykadia (Novartis) - The Rise of Kinase Inhibitors
      • 6.1.2.1 Market Potential
    • 6.1.3 Cyramza (Eli Lilly) - A Breakthrough for Gastric Cancer?
      • 6.1.3.1 Market Potential
  • 6.2 Approved Treatments in 2013
    • 6.2.1 Imbruvica (Pharmacyclics)
      • 6.2.1.1 Market Potential
    • 6.2.2 Gazyva (Roche) - The First Breakthrough Therapy
      • 6.2.2.1 Market Potential
    • 6.2.3 Gilotrif (Boehringer Ingelheim)
      • 6.2.3.1 Market Potential
    • 6.2.4 Mekinist (GSK) - A First-in-Class Treatment for Melanoma
      • 6.2.4.1 Market Potential
    • 6.2.5 Tafinlar (GSK) - A Partner for Mekinist
      • 6.2.5.1 Market Potential
    • 6.2.6 Kadycla (Roche) - A Future Star
      • 6.2.6.1 Market Potential - A Replacement for Herceptin?
    • 6.2.7 Pomalyst (Celgene)
      • 6.2.7.1 Market Potential
  • 6.3 Drugs Approved in 2012 - How They're Doing Now
    • 6.3.1 Afinitor (Novartis) - Already a Blockbuster
      • 6.3.1.1 Market Potential
    • 6.3.2 Bosulif (Pfizer) - How Will it Perform?
      • 6.3.2.1 Market Potential
    • 6.3.3 Cometriq (Exelixis)
      • 6.3.3.1 Market Potential
    • 6.3.4 Erivedge (Roche) - Will It Become a Blockbuster?
      • 6.3.4.1 Market Potential
    • 6.3.5 Iclusig (Ariad)
      • 6.3.5.1 Market Potential - Wider Uses?
    • 6.3.6 Inlyta (Pfizer) - A Good Second-Line Option?
      • 6.3.6.1 Market Potential
    • 6.3.7 Kyprolis (Amgen)
      • 6.3.7.1 Market Potential
    • 6.3.8 Marqibo (Talon) - Will Its Revenue Grow?
      • 6.3.8.1 Market Potential
    • 6.3.9 Perjeta (Roche) - Joining the HER2 Family
      • 6.3.9.1 Market Potential
    • 6.3.10 Stivarga (Bayer)
      • 6.3.10.1 Market Potential
    • 6.3.11 Synribo (Teva)
      • 6.3.11.1 Market Potential
    • 6.3.12 Votrient (GSK)
      • 6.3.12.1 Market Potential
    • 6.3.13 Xtandi (Medivation) - Quickly Becoming a Popular Choice
      • 6.3.13.1 Market Potential
    • 6.3.14 Zaltrap (Sanofi)
      • 6.3.14.1 Market Potential

7. Leading Companies for Cancer Treatments, 2014

  • 7.1 Anti-Cancer Drug Market Dominated by Seven Companies
  • 7.2 Roche - Leader of the Pack
    • 7.2.1 Oncology Pipeline - Investment in the Future
    • 7.2.2 Roche's Future Direction in Cancer Treatment
  • 7.3 Novartis - Closing the Gap on Roche
    • 7.3.1 Oncology R&D Pipeline - What's the Potential?
    • 7.3.2 Future Directions for Novartis
  • 7.4 Celgene - Pressing Need to Diversify?
    • 7.4.1Celgene's Oncology Pipeline - Safeguarding the Future
    • 7.4.2 Future Directions for Celgene
  • 7.5 Eli Lilly - Reliant on Alimta
    • 7.5.1 Oncology R&D Pipeline - What Potential Exists?
    • 7.5.2 The Future Direction of Eli Lilly
  • 7.6 AstraZeneca - Climbing up the Ladder
    • 7.6.1 Oncology Pipeline - Showing Promise
    • 7.6.2 The Future Direction of AstraZeneca
  • 7.7 Bristol-Myers Squibb
    • 7.7.1 Oncology R&D Pipeline - What Potential Exists?
    • 7.7.2 Future Direction of BMS
  • 7.8 Merck & Co. - Prominent in Vaccines
    • 7.8.1 Oncology Pipeline - Greater Focus on Cancer
    • 7.8.2 The Future Direction of Merck

8. R&D Pipelines for Cancer Treatment

  • 8.1 Breast Cancer Drugs Under Development
    • 8.1.1 Neratinib (Puma Pharmaceuticals)
    • 8.1.2 Palbociclib (Pfizer)
    • 8.1.3 Veliparib (Abbvie)
    • 8.1.4 NeuVax (Galena Biopharma)
    • 8.1.5 Entinostat (Syndax)
  • 8.2 Prostate Cancer Drugs Under Development
    • 8.2.1 OMD-201 (Orion)
    • 8.2.2 Tasquinimod (Active Biotech)
    • 8.2.3 EMD-525797 (EMD Serono)
    • 8.2.4 PROSTVAC (Bavarian Nordic)
  • 8.3 Lung Cancer Drugs Under Development
    • 8.3.1 Tecemotide (Merck Serono)
    • 8.3.2 RG7446 (Roche)
    • 8.3.3 Nivolumab (Bristol-Myers Squibb)
    • 8.3.4 MEDI4736 (AstraZeneca)
    • 8.3.5 TG4010 (Transgene)
  • 8.4 Colorectal Cancer Drugs Under Development
    • 8.4.1 Imprime PGG (Biothera)
    • 8.4.2 Xilonix (Xbiotech)
    • 8.4.3 TAS-102 (Taiho Pharmaceuticals)
    • 8.4.4 HA-Irinotecan (Alchemia)
    • 8.4.5 Aptocine (Light Sciences Oncology)
  • 8.5 Cervical Cancer Drugs Under Development
    • 8.5.1 ADXS-HPV (Advaxis)
    • 8.5.2 V503 (Merck & Co.)
    • 8.5.3 VGX-3100 (Inovio Pharmaceuticals)
  • 8.6 Stomach Cancer Drugs Under Development
    • 8.6.1 Rilotumumab (Amgen)
    • 8.6.2 Onartuzumab (Roche)
    • 8.6.3 Apatinib (Jiangsu Hengrui Medicine)
  • 8.7 Liver Cancer Drugs Under Development
    • 8.7.1 Tivantinib (ArQule)
    • 8.7.2 Lenvatinib (Eisai Co.)
    • 8.7.3 Pexa-Vec9 (Jennerex Biotherapeutics)
    • 8.7.4 Brivanib (Bristol-Myers Squibb)
    • 8.7.5 Muparfostat (Progen Pharmaceuticals)
  • 8.8 Ovarian Cancer Drugs Under Development
    • 8.8.1 Farletuzumab (Eisai)
    • 8.8.2 Niraparib (TESARO)
    • 8.8.3 Trebananib (Amgen)
    • 8.8.4 SG2000 (Spirogen)
  • 8.9 Bladder Cancer Drugs Under Development
    • 8.9.1 Vesimune (Telormedix)
    • 8.9.2 HS-410 (Heat Biologics)
    • 8.9.3 EOquin (Allergan)
  • 8.10 Non-Hodgkin's Lymphoma Drugs Under Development
    • 8.10.1 Idelalisib (Gilead)
    • 8.10.2 IPI-145 (Infinity Pharmaceuticals)
    • 8.10.3 ABT-199 (AbbVie)
    • 8.10.4 GS-9973 (Gilead)
  • 8.11 Leukaemia Drugs Under Development
    • 8.11.1 Dinaciclib (Merck)
    • 8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
    • 8.11.3 Vosaroxin (Sunesis)
  • 8.12 Kidney Cancer Drugs Under Development
    • 8.12.1 IMA901 (Immatics)
    • 8.12.2 ASG-003 (Argos Therapeutics)
    • 8.12.3 Nilovumab (Bristol-Myers Squibb)
    • 8.12.4 TRC105 (Tracon Pharmaceuticals)
  • 8.13 Pancreatic Cancer Drugs Under Development
    • 8.13.1 Algenpantucel-L (NewLink Genetics)
    • 8.13.2 MM-398 (Merrimack)
    • 8.13.3 MK-0752 (Merck & Co.)

9. Qualitative Analysis of the Anti-Cancer Drug Market 2014-2024

  • 9.1 SWOT Analysis of the Anti-Cancer Drugs Market
    • 9.1.1 Strengths of the Market
      • 9.1.1.1 The Rising Incidence of Cancer
      • 9.1.1.2 Ample Treatment Options Available
    • 9.1.2 Weaknesses
      • 9.1.2.1 The Challenges of Drug Development
      • 9.1.2.2 The Complex Nature of Cancer
    • 9.1.3 Opportunities in the Anti-Cancer Drugs Market
      • 9.1.3.1 The Advancement of Research
      • 9.1.3.2 A Shift Towards Personalisation
    • 9.1.4 Threats Facing the Anti-Cancer Drugs Market
      • 9.1.4.1 The Threat of Regulation
  • 9.2 STEP Analysis of the Anti-Cancer Drugs Market
    • 9.2.1 Social Factors: The Cost of Living Longer
    • 9.2.2 Technological Developments: Making the Market Move Forward
    • 9.2.3 Economic Pressure: Treatment's Hefty Price Tag
    • 9.2.4 Political Issues: Governmental Involvement in Treatment

10. Research Interviews

  • 10.1 Interview with Mr Thomas Felzmann, CEO, Activartis Biotech GmbH, Vienna, Austria
    • 10.1.1 Activartis Biotech and AV0113
  • 10.2 Interview with Professor Philip Rudland, Chair of Biochemistry at the University of Liverpool
    • 10.2.1 Identifying Markers in Cancer Cells
    • 10.2.2 The Importance of Protein Expression
    • 10.2.3. The Advancement of Diagnostics
    • 10.2.4 The Future of the Anti-Cancer Drug Market
  • 10.3 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
    • 10.3.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
    • 10.3.2 On the Evaluation of New Targets for Anti-Cancer Drugs
    • 10.3.3 On Drug Resistance and Targeted Therapies
    • 10.3.4 On the Future of Traditional Chemotherapy
    • 10.3.5 On Future Developments in the Anti-Cancer Field
  • 10.4 Interview with Dr Neil Butt, Director, Antitope Ltd.
    • 10.4.1 On Immunogenicity in Therapeutic Proteins
    • 10.4.2 On Antitope's Technologies to Assess and Reduce Immunogenicity
    • 10.4.3 On an Alternative Way of Reducing Immunogenicity
    • 10.4.4 On Biosimilars
    • 10.4.5 On Future Developments in that Field

11. Conclusions of the Study

  • 11.1 The Top 25 Drugs in the Cancer Treatment Market
  • 11.2 Immunotherapies - The Future of the Market
  • 11.3 Patent Expiries and the Impact of Biosimilars
  • 11.4 The US - Still the Largest National Market
  • 11.5 China and Brazil Will Lead the Emerging Markets
  • 11.6 Treatment - It's Personal
  • 11.7 The Anti-Cancer Drug Pipeline Remains Strong
  • 11.8 Concluding Remarks

List of Tables

  • Table 1.1 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2013-2018
  • Table 1.2 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
  • Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013
  • Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013
  • Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013
  • Table 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 3.2 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2012-2013
  • Table 3.3 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue Forecast ($bn), CAGR (%) and Market Share (%), 2013, 2018 and 2024
  • Table 3.4 Global Immunotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 3.5 Global Chemotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 3.6 Global Targeted Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 3.7 Global Hormone Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.1 Anti-Cancer Drugs Market Revenue ($bn) and Market Share (%) by Leading Country, 2013, 2018, 2024
  • Table 4.2 Leading National Anti-Cancer Drugs Markets: Revenue Forecast ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2014-2024
  • Table 4.3 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.4 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.5 EU5 Anti-Cancer Drugs Market Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.6 The BRIC Countries Anti-Cancer Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.7 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.8 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.9 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 4.10 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.1 Top 25 Anti-Cancer Drugs: Revenue ($bn) and Market Share (%), 2013
  • Table 5.2 Top 10 Anti-Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2013, 2018, 2024
  • Table 5.3 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024
  • Table 5.4 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024 (Contd.)
  • Table 5.5 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024 (Contd.)
  • Table 5.6 Avastin Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.7 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.8 Herceptin Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.9 Herceptin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.10 Rituxan/MabThera Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.11 Rituxan/MabThera Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.12 Glivec Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.13 Glivec Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.14 Revlimid Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.15 Revlimid Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.16 Alimta Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.17 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.18 Velcade Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.19 Velcade Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.20 Erbitux Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.21 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.22 Gardasil Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.23 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.24 Zytiga Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
  • Table 5.25 Zytiga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.26 Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.27 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.28 Tarceva Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.29 Tarceva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.30 Afinitor Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.31 Afinitor Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.32 Sprycel Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.33 Sprycel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.34 Tasigna Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.35 Tasigna Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.36 Sutent Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.37 Sutent: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.38 Nexavar Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.39 Nexavar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.40 Xgeva Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.41 Xgeva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.42 Zoladex Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.43 Zoladex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.44 Yervoy Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
  • Table 5.45 Yervoy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.46 Vidaza Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.47 Vidaza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.48 Treanda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
  • Table 5.49 Treanda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.50 Temodar Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.51 Temodar Revenue Forecast (%bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 5.52 Faslodex Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.53 Faslodex Revenue Forecast ($bn), Annual Growth (%) and CAGR, 2014-2024
  • Table 5.54 Abraxane Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
  • Table 5.55 Abraxane: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.1 Beleodaq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.2 Zykadia: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.3 Cyramza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.4 Imbruvica: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.5 Gazyva: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.6 Gilotrif: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.7 Mekinist: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.8 Tafinlar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.9 Kadcyla: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.10 Pomalyst: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.11 Bosulif: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.12 Cometriq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.13 Erivedge: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.14 Iclusig: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.15 Inlyta: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.16 Kyprolis: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.17 Marqibo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.18 Perjeta: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.19 Stivarga: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.20 Synribo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.21 Votrient: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.22 Xtandi: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 6.23 Zaltrap: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
  • Table 7.1 Anti-Cancer Drug Revenues ($bn) and Market Shares (%) of Leading Companies, 2012-2013
  • Table 7.2 Roche - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
  • Table 7.3 Roche's Anti-Cancer Drug Development Pipeline, 2013
  • Table 7.4 Novartis - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
  • Table 7.5 Novartis' Anti-Cancer Drug Pipeline, 2013
  • Table 7.6 Celgene - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
  • Table 7.7 Celgene's Anti-Cancer Drug Pipeline, 2013
  • Table 7.8 Eli Lilly - Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
  • Table 7.9 Eli Lilly's Anti-Cancer Drug Pipeline, 2013
  • Table 7.10 AstraZeneca - Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
  • Table 7.11 AstraZeneca's Anti-Cancer Drug Pipeline, 2013
  • Table 7.12 Bristol-Myers Squibb - Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
  • Table 7.13 Bristol-Myers Squibb Anti-Cancer Drug Pipeline, 2013
  • Table 7.14 Merck - Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
  • Table 7.15 Merck's Anti-Cancer Drug Pipeline, 2013
  • Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
  • Table 8.2 Breast Cancer Drugs under Development, 2013
  • Table 8.3 Prostate Cancer Drugs under Development, 2013
  • Table 8.4 Lung Cancer Drugs under Development, 2013
  • Table 8.5 Colorectal Cancer Drugs under Development, 2013
  • Table 8.6 Cervical Cancer Drugs under Development, 2013
  • Table 8.7 Stomach Cancer Drugs under Development, 2013
  • Table 8.8 Liver Cancer Drugs under Development, 2013
  • Table 8.9 Ovarian Cancer Drugs under Development, 2013
  • Table 8.10 Bladder Cancer Drugs under Development, 2013
  • Table 8.11 Non-Hodgkin's Lymphoma Drugs under Development, 2013
  • Table 8.12 Leukaemia Drugs under Development, 2013
  • Table 8.13 Kidney Cancer Drugs under Development, 2013
  • Table 8.14 Pancreatic Cancer Drugs under Development, 2013
  • Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2014
  • Table 9.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2014

List of Figures

  • Figure 1.1 Forecast Global Population Over the Age of 65 Years Old (millions), Annual Growth Rate (%), 2013-2024
  • Figure 1.2 Anti-Cancer Market Segmentation, 2014
  • Figure 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
  • Figure 3.2 Global Anti-Cancer Drugs Market: Drivers and Restraints, 2014-2024
  • Figure 3.3 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2013
  • Figure 3.4 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2018
  • Figure 3.5 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2024
  • Figure 3.6 Global Immunotherapy Market: Revenue Forecast ($bn), 2014-2024
  • Figure 3.7 Immunotherapy Market: Drivers and Restraints, 2014-2024
  • Figure 3.8 Global Chemotherapy Market: Revenue Forecast ($bn), 2014-2024
  • Figure 3.9 Chemotherapy Market: Drivers and Restraints, 2014-2024
  • Figure 3.10 Global Targeted Therapy Market: Revenue Forecast ($bn), 2014-2024
  • Figure 3.11 Targeted Therapy Market: Drivers and Restraints, 2014-2024
  • Figure 3.12 Global Hormone Therapy Market: Revenue Forecast ($bn), 2014-2024
  • Figure 3.13 Hormone Therapy Market: Drivers and Restraints, 2014-2024
  • Figure 4.1 Developed National Markets: Drivers and Restraints, 2014-2024
  • Figure 4.2 Emerging National Markets: Drivers and Restraints, 2014-2024
  • Figure 4.3 Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2013
  • Figure 4.4 Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2018
  • Figure 4.5 Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2024
  • Figure 4.6 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), 2014-2024
  • Figure 4.7 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), 2014-2024
  • Figure 4.8 The EU5 Anti-Cancer Drugs Markets: Revenue Forecast ($bn), 2014-2024
  • Figure 4.9 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2013
  • Figure 4.10 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2018
  • Figure 4.11 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2024
  • Figure 4.12 BRIC Countries Anti-Cancer Drugs Market Share (%), 2013
  • Figure 4.13 BRIC Countries Anti-Cancer Drugs Market Share (%), 2018
  • Figure 4.14 BRIC Countries Anti-Cancer Drug Market Share (%), 2024
  • Figure 4.15 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
  • Figure 4.16 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
  • Figure 4.17 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
  • Figure 4.18 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
  • Figure 5.1 Top 10 Anti-Cancer Drugs: Market Share (%), 2013
  • Figure 5.2 Top 10 Anti-Cancer Drugs: Market Share (%), 2018
  • Figure 5.3 Top 10 Anti-Cancer Drugs: Market Share (%), 2024
  • Figure 5.4 Avastin Revenue ($bn), 2010-2013
  • Figure 5.5 Avastin Revenue Forecast ($bn), 2014-2024
  • Figure 5.6 Avastin: Drivers and Restraints, 2014-2024
  • Figure 5.7 Herceptin Revenue ($bn), 2010-2013
  • Figure 5.8 Herceptin Revenue Forecast ($bn), 2014-2024
  • Figure 5.9 Herceptin: Drivers and Restraints, 2014-2024
  • Figure 5.10 Rituxan/MabThera Revenue ($bn), 2010-2013
  • Figure 5.11 Rituxan/MabThera Revenue Forecast ($bn), 2014-2024
  • Figure 5.12 Rituxan/MabThera: Drivers and Restraints, 2014-2024
  • Figure 5.13 Glivec Revenue ($bn), 2010-2013
  • Figure 5.14 Glivec Revenue Forecast ($bn), 2014-2024
  • Figure 5.15 Glivec: Drivers and Restraints, 2014-2024
  • Figure 5.16 Revlimid Revenue ($bn), 2010-2013
  • Figure 5.17 Revlimid Revenue Forecast ($bn), 2014-2024
  • Figure 5.18 Revlimid: Drivers and Restraints, 2014-2024
  • Figure 5.19 Alimta Revenue ($bn), 2010-2013
  • Figure 5.20 Alimta Revenue Forecast ($bn), 2014-2024
  • Figure 5.21 Alimta: Drivers and Restraints, 2014-2024
  • Figure 5.22 Velcade Revenue ($bn), 2010-2013
  • Figure 5.23 Velcade Revenue Forecast ($bn), 2014-2024
  • Figure 5.24 Velcade: Drivers and Restraints, 2014-2024
  • Figure 5.25 Erbitux Revenue ($bn), 2010-2013
  • Figure 5.26 Erbitux Revenue Forecast ($bn), 2014-2024
  • Figure 5.27 Erbitux: Drivers and Restraints, 2014-2024
  • Figure 5.28 Gardasil Revenue ($bn), 2010-2013
  • Figure 5.29 Gardasil Revenue Forecast ($bn), 2014-2024
  • Figure 5.30 Gardasil: Drivers and Restraints, 2014-2024
  • Figure 5.31 Zytiga Revenue ($bn), 2011-2013
  • Figure 5.32 Zytiga Revenue Forecast ($bn), 2014-2024
  • Figure 5.33 Zytiga: Drivers and Restraints, 2014-2024
  • Figure 5.34 Xeloda Revenue ($bn), 2010-2013
  • Figure 5.35 Xeloda Revenue Forecast ($bn), 2014-2024
  • Figure 5.36 Xeloda: Drivers and Restraints, 2014-2024
  • Figure 5.37 Tarceva Revenue, 2010-2013
  • Figure 5.38 Tarceva: Revenue Forecast ($bn), 2014-2024
  • Figure 5.39 Tarceva: Drivers and Restraints, 2014-2024
  • Figure 5.40 Afinitor Revenue ($bn), 2010-2013
  • Figure 5.41 Afinitor Revenue Forecast ($bn), 2014-2024
  • Figure 5.42 Afinitor: Drivers and Restraints, 2014-2024
  • Figure 5.43 Sprycel Revenue ($bn), 2010-2013
  • Figure 5.44 Sprycel Revenue Forecast ($bn), 2014-2024
  • Figure 5.45 Sprycel: Drivers and Restraints, 2014-2024
  • Figure 5.46 Tasigna Revenue ($bn), 2010-2013
  • Figure 5.47 Tasigna Revenue Forecast ($bn), 2014-2024
  • Figure 5.48 Tasigna: Drivers and Restraints, 2014-2024
  • Figure 5.49 Sutent Revenue ($bn), 2010-2013
  • Figure 5.50 Sutent: Revenue Forecast ($bn), 2014-2024
  • Figure 5.51 Sutent: Drivers and Restraints, 2014-2024
  • Figure 5.52 Nexavar Revenue ($bn), 2010-2013
  • Figure 5.53 Nexavar: Revenue Forecast ($bn), 2014-2024
  • Figure 5.54 Nexavar: Drivers and Restraints, 2014-2024
  • Figure 5.55 Xgeva Revenue ($bn), 2010-2013
  • Figure 5.56 Xgeva Revenue Forecast ($bn), 2014-2024
  • Figure 5.57 Xgeva: Drivers and Restraints, 2014-2024
  • Figure 5.58 Zoladex Revenue ($bn), 2010-2013
  • Figure 5.59 Zoladex: Revenue Forecast ($bn), 2014-2024
  • Figure 5.60 Zoladex: Drivers and Restraints, 2014-2024
  • Figure 5.61 Yervoy Revenue ($bn), 2011-2013
  • Figure 5.62 Yervoy Revenue Forecast ($bn), 2014-2024
  • Figure 5.63 Yervoy: Drivers and Restraints, 2014-2024
  • Figure 5.64 Vidaza Revenue ($bn), 2011-2013
  • Figure 5.65 Vidaza: Revenue Forecast ($bn), 2014-2024
  • Figure 5.66 Vidaza: Drivers and Restraints, 2014-2024
  • Figure 5.67 Treanda Revenue ($bn), 2011-2013
  • Figure 5.68 Treanda Revenue Forecast ($bn), 2014-2024
  • Figure 5.69 Treanda: Drivers and Restraints, 2014-2024
  • Figure 5.70 Temodar Revenue ($bn), 2010-2013
  • Figure 5.71 Temodar Revenue Forecast ($bn), 2014-2024
  • Figure 5.72 Temodar: Drivers and Restraints, 2014-2024
  • Figure 5.73 Faslodex Revenue ($bn), 2010-2013
  • Figure 5.74 Faslodex Revenue Forecast ($bn), 2014-2024
  • Figure 5.75 Faslodex: Drivers and Restraints, 2014-2024
  • Figure 5.76 Abraxane Revenue ($bn), 2010-2013
  • Figure 5.77 Abraxane: Revenue Forecast ($bn), 2014-2024
  • Figure 5.78 Abraxane: Drivers and Restraints, 2014-2024
  • Figure 6.1 Beleodaq: Revenue Forecast ($bn), 2014-2024
  • Figure 6.2 Zykadia: Revenue Forecast ($bn), 2014-2024
  • Figure 6.3 Cyramza: Revenue Forecast ($bn), 2014-2024
  • Figure 6.4 Imbruvica: Revenue Forecast ($bn), 2014-2024
  • Figure 6.5 Gazyva: Revenue Forecast ($bn), 2014-2024
  • Figure 6.6 Gilotrif: Revenue Forecast ($bn), 2014-2024
  • Figure 6.7 Mekinist: Revenue Forecast ($bn), 2014-2024
  • Figure 6.8 Tafinlar: Revenue Forecast ($bn), 2014-2024
  • Figure 6.9 Kadcyla: Revenue Forecast ($bn), 2014-2024
  • Figure 6.10 Pomalyst: Revenue Forecast ($bn), 2014-2024
  • Figure 6.11 Bosulif: Revenue Forecast ($bn), 2014-2024
  • Figure 6.12 Cometriq: Revenue Forecast ($bn), 2014-2024
  • Figure 6.13 Erivedge: Revenue Forecast ($bn), 2014-2024
  • Figure 6.14 Iclusig: Revenue Forecast ($bn), 2014-2024
  • Figure 6.15 Inlyta: Revenue Forecast ($bn), 2014-2024
  • Figure 6.16 Kyprolis: Revenue Forecast ($bn), 2014-2024
  • Figure 6.17 Marqibo: Revenue Forecast ($bn), 2014-2024
  • Figure 6.18 Perjeta: Revenue Forecast ($bn), 2014-2024
  • Figure 6.19 Stivarga: Revenue Forecast ($bn), 2014-2024
  • Figure 6.20 Synribo: Revenue Forecast ($bn), 2014-2024
  • Figure 6.21 Votrient: Revenue Forecast ($bn), 2014-2024
  • Figure 6.22 Xtandi: Revenue Forecast ($bn), 2014-2024
  • Figure 6.23 Zaltrap: Revenue Forecast ($bn), 2014-2024
  • Figure 7.1 Anti-Cancer Drugs Market Share (%) by Leading Company, 2012
  • Figure 7.2 Anti-Cancer Drugs Market Share (%) by Leading Company, 2013
  • Figure 7.3 Roche's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 7.4 Novartis' Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 7.5 Celgene's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 7.6 Eli Lilly's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 7.7 AstraZeneca's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 7.8 Bristol-Myers Squibb's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 7.9 Merck's Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
  • Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
  • Figure 12.1 Top 25 Anti-Cancer Drugs: Revenues ($bn), 2013

Companies Listed

  • AbbVie
  • Abraxis BioScience
  • Actavis
  • Activartis Biotech
  • Active Biotech
  • Advaxis
  • Advenchen Laboratories
  • Alchemia
  • Allergan
  • Amgen
  • Antitope
  • Apotex
  • Argos Therapeutics
  • Ariad Pharmaceuticals
  • ArQule
  • Astellas
  • AstraZeneca
  • Bavarian Nordic
  • Bayer
  • Biocon
  • Biothera
  • BioXpress Therapeutics
  • Bristol-Myers Squibb
  • Bukwang Pharmaceutical Company
  • Celgene
  • Cephalon
  • Cipla
  • Cyclacel
  • Dendreon
  • Dr. Reddy's Laboratories
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • EMD Serono
  • Exelixis
  • Food and Drug Administration (FDA, US)
  • Galena Biopharma
  • Genentech
  • Gilead
  • GlaxoSmithKline (GSK)
  • Heat Biologics
  • Immatics Biotechnologies
  • Infinity Pharmaceuticals
  • Inovio Pharmaceuticals
  • Intas Biopharmaceuticals
  • Jennerex Biotherapeutics
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson
  • Light Sciences Oncology
  • LSK BioPartners
  • McGill University
  • Medivation
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Merrimack
  • Ministry of Health, Labour and Welfare (Japan)
  • NewLink
  • NHS (UK)
  • NICE (UK)
  • Novartis
  • Onyx
  • Orion
  • OSI Pharmaceuticals
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmacyclics
  • Progen Pharmaceuticals
  • Puma Biotechnology
  • Roche
  • Sanofi-Aventis
  • Spectrum Pharmaceuticals
  • Spirogen
  • Sun Pharma
  • Sunesis Pharmaceuticals
  • Syndax
  • Taiho
  • Takeda
  • Talon Therapeutics
  • Telormedix
  • TESARO
  • Teva Pharmaceuticals
  • Tracon Pharma
  • Transgene
  • University of Liverpool
  • Vaccinogen
  • World Health Organization (WHO)
  • Xbiotech
Back to Top